FDA import alert lists updated GLP-1 bulk-drug entry and Green List guidance

FDA's current Import Alert 66-80 page carries a publication date of October 9, 2026. It concerns detention without physical examination of imported GLP-1 receptor agonist bulk drug substances. The page describes revisions to documentation guidance, Green List entries and product codes; this is not evidence that every provision of the alert was first created today.

The alert says FDA divisions may detain offered shipments of GLP-1 active pharmaceutical ingredients without physical examination, except for the products and firms identified on its Green List. That exception is specific to the listed firm and product. It does not establish approval of a finished compounded drug or an entitlement for a patient to obtain one.

The revision note adds orforglipron active ingredient to three manufacturers' Green List entries and an orforglipron SDD drug-product intermediate to one. It also identifies new orforglipron and hormone product codes. These are entries within GLP-1 import controls, not a declaration that every GLP-1 substance is a peptide or that all research peptides may now be prescribed.

For manufacturers seeking Green List inclusion, the alert gives examples of evidence intended to address the appearance of a violation. They include manufacturing-site information, certificates of analysis, release specifications and testing methods, stability records, process validation and quality-system records. The guidance says supporting evidence may be provided before shipment to help review and avoid import delays.

The alert's background says FDA evaluated 48 GLP-1 API sites and found 21% noncompliant through manufacturing-quality evidence or untimely responses to records requests. This describes the agency's assessed sites, not 21% of all GLP-1 medicines, all compounding pharmacies or patients. The page does not date each evaluation or establish a new October 9 clinical adverse-event rate.

Limits: FDA labels the alert guidance for field personnel that does not itself create rights or bind FDA or the public. Green List status can change if the agency receives information about noncompliance. Import screening, finished-drug approval, compounding eligibility and treatment decisions are separate questions. This brief supplies no buying, dosing or injection instructions and does not announce a general change to peptide prescribing policy.